Global Information
회사소개 | 문의 | 위시리스트

세계의 생물방어 시장 : 제품별, 지역별 - 성장, 동향, 예측(2018-2023년)

Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023)

리서치사 Mordor Intelligence LLP
발행일 2018년 06월 상품 코드 659347
페이지 정보 영문 107 Pages
가격
US $ 4,250 ₩ 5,033,000 PDF by E-mail (Single User License)
US $ 4,500 ₩ 5,329,000 PDF by E-mail (Team License: Up to 7 Users)
US $ 7,000 ₩ 8,290,000 PDF by E-mail (Site License)
US $ 8,750 ₩ 10,362,000 PDF by E-mail (Corporate License)


세계의 생물방어 시장 : 제품별, 지역별 - 성장, 동향, 예측(2018-2023년) Global Biodefense Market - Segmented by Product and Geography - Growth, Trends, and Forecast (2018 - 2023)
발행일 : 2018년 06월 페이지 정보 : 영문 107 Pages

세계의 생물방어 시장은 2018-2023년간 6.5%의 연평균 복합 성장률(CAGR)로 성장을 지속할 전망입니다. 생물 테러리즘은 인류에게 있어서 유해한 생물제를 사용하는 것입니다. 생물방어에는 생물제로부터 보호하기 위한 의료 조치가 포함됩니다. 나노테크놀러지, 데이터베이스 관리 시스템, 고도의 검출기 하드웨어, 포렌식 부문에서의 병원체 검출용 유전자 칩 등 기술적 진보가 시장 성장을 촉진하는 주요인입니다. 또, 백신 생산 증가, 포렌식 강화, 신속한 진단 절차와 검출 기술도 시장 성장을 촉진할 것으로 예측됩니다. 또 최근 니파 바이러스, 에볼라 바이러스, 지카 바이러스 발생에 의해 연구개발(R&D) 자금이 증가하고 있습니다. 선진국가 지방정부의 생물방어에 대한 투자 증가는 예측기간 중 시장 성장을 촉진할 것으로 예상됩니다.

세계의 생물방어(Biodefense) 시장을 조사했으며, 전체적인 시장 동향, 제품 및 지역별 동향, 시장 성장 영향요인, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 시장 정의

제2장 조사 방법

제3장 주요 요약

제4장 주요 추론

제5장 시장 개요

  • 현재의 시장 시나리오
  • 파이프라인 분석
  • Porter's Five Forces 분석
    • 공급업체의 협상력
    • 소비자의 협상력
    • 신규 진출기업의 위협
    • 대체 제품과 서비스의 위협
    • 업계 내 경쟁
  • 규제 시나리오

제6장 성장 촉진요인 및 저해요인, 기회와 과제 분석(DROC)

  • 시장 성장 촉진요인
    • 호의적인 정부 정책
    • 선진국가 지방정부의 투자 증가
    • 급속한 기술 진보
  • 시장 성장 저해요인
    • 개발도상국 및 선진국의 낮은 시장 침투율
  • 시장 기회
  • 주요 과제

제7장 시장 세분화

  • 제품별
    • 탄저균
    • 보툴리누스 중독
    • 천연두
    • 세포핵
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동 및 아프리카
    • 남미

제8장 경쟁 구도

  • 기업 인수합병(M&A) 분석
  • 합의, 협력, 제휴
  • 신제품 발매

제9장 주요 기업

  • Alnylam Pharmaceuticals Inc.
  • Bavarian Nordic
  • Cleveland BioLabs
  • DynPort Vaccine Company LLC
  • Elusys Therapeutics Inc.
  • Emergent BioSolutions Inc.
  • Ichor Medical Systems
  • Ology Bioscience
  • PharmAthene Inc.
  • SIGA Technologies

제10장 시장 전망

LSH 18.07.17

The global biodefense market is expected to register a CAGR of 6.5% during the forecast period, 2018 to 2023. Bioterrorism is the use of biological agents that are harmful for mankind. Biodefense includes medical measures to protect from biological agents. Key factors driving the market growth are rise in technological advancement, such as nanotechnology, database management systems, advanced detector hardware, and gene chips for pathogen detection in the forensic department. Also, the rise in the production of vaccines, enhanced forensics, and quick diagnostic procedures and detection techniques are the factors expected to drive the market growth. Additionally, due to the recent outbreak of Nipah, Ebola, and Zika viruses governments are increasing R&D funding. Increasing investments by regional governments of developed countries for biodefense are also expected to enhance the market growth over the forecast period.

Favorable Government Initiatives

Governments spend huge sums of money every year for the R&D of vaccines in order stay prepared for any bioterrorism attacks. Pharmaceutical companies operating in the biodefense sector have huge opportunities to expand due to governments' drive to be prepare for any kind of bioterrorism. For instance, in 2004, the US congress passed the Project Bioshield act, calling for USD 5 billion investment for purchasing vaccines which can be used in the event of a bioterrorist attack. This act was designed to acquire medical countermeasures to biological, chemical, radiological, and nuclear agents for civilian use. Such government initiatives are expected to propel the growth of the biodefense market.

Other factors driving this market are rapid technological advancements and increasing investments by regional governments in developed countries.

Low Market Penetration in Developing and Underdeveloped Countries

The growth of biodefense market may be hampered by the low market penetration in the developing and underdeveloped countries. Limited government interventions and funding for biodefense materials are some of the major reasons restraining the growth of the market. Developed countries have more resources to be prepared for a bio war when compared to developing countries.

North America to Dominate the Market

North America dominated the global biodefense market in 2017, which can be attributed to the increase in government funding to generate and stockpile sufficient vaccines to be used against anthrax through various initiative, such as BioShield act, Biomedical Advanced Research and Development Authority (BARDA), and Joint Program Executive Office for Chemical & Biological Defense. For instance, the US Department of Health and Human Services announced it plans to spend more than USD 25 million on an anthrax antitoxin, as a part of an emergency preparedness plan in 2018. In May 2018, the Coalition for Epidemic Preparedness Innovations (CEPI) announced that USD 25 million was granted to advance the development and manufacture of a vaccine against the Nipah virus (NiV) to major market players, like Profectus BioSciences Inc. and Emergent BioSolutions Inc. The above mentioned initiatives by government are expected to boost the growth of the market in the region.

Key Developments in the Market:

  • February 2018 - Bavarian Nordic A/S announced positive results from a Phase 3 pivotal study of its investigational and non-replicating smallpox vaccine, IMVAMUNE
  • March 2017 - PharmAthene Inc. a biodefense company developing medical countermeasures against anthrax, announced that it has established a record date and meeting date for a special meeting of stockholders to vote upon, among other things, the proposal to adopt the agreement and plan of merger and reorganization involving PharmAthene and Altimmune Inc.
  • Major Players: ALNYLAM PHARMACEUTICALS INC., BAVARIAN NORDIC, CLEVELAND BIOLABS, DYNPORT VACCINE COMPANY LLC, ELUSYS THERAPEUTICS INC., EMERGENT BIOSOLUTIONS INC., ICHOR MEDICAL SYSTEMS, OLOGY BIOSCIENCE, PHARMATHENE INC., AND SIGA TECHNOLOGIES INDUSTRIES LTD, amongst others.

Reasons to Purchase this Report:

  • Current and future global biodefense market outlook in the developed and emerging markets
  • Analysis of various perspectives of the market with the help of Porter's five forces analysis
  • The segment that is expected to dominate the market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, market shares, and strategies employed by the major market players
  • 3 months analyst support, along with the Market Estimate sheet (in excel)

Customization of the report:

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs

Table of Contents

1. Introduction

  • 1.1. Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1. Current Market Scenario
  • 5.2. Pipeline Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining Power of Suppliers
    • 5.3.2. Bargaining Power of Consumers
    • 5.3.3. Threat of New Entrants
    • 5.3.4. Threat of Substitute Product and Services
    • 5.3.5. Competitive Rivalry within the Industry
  • 5.4. Regulatory Scenario

6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)

  • 6.1. Market Drivers
    • 6.1.1. Favorable Government Initiatives
    • 6.1.2. Increasing Investments by the Regional Governments in the Developed Countries
    • 6.1.3. Rapid Technological Advancements
  • 6.2. Market Restraints
    • 6.2.1. Low Market Penetration in Developing and Underdeveloped Countries
  • 6.3. Opportunities
  • 6.4. Key Challenges

7. Market Segmentation

  • 7.1. By Product
    • 7.1.1. Anthrax
    • 7.1.2. Botulism
    • 7.1.3. Smallpox
    • 7.1.4. Nuclear
    • 7.1.5. Others
  • 7.2. By Geography
    • 7.2.1. North America
      • 7.2.1.1. United States
      • 7.2.1.2. Canada
      • 7.2.1.3. Mexico
    • 7.2.2. Europe
      • 7.2.2.1. France
      • 7.2.2.2. Germany
      • 7.2.2.3. United Kingdom
      • 7.2.2.4. Italy
      • 7.2.2.5. Spain
      • 7.2.2.6. Rest Of Europe
    • 7.2.3. Asia-Pacific
      • 7.2.3.1. China
      • 7.2.3.2. Japan
      • 7.2.3.3. India
      • 7.2.3.4. Australia & New Zealand
      • 7.2.3.5. South Korea
      • 7.2.3.6. Rest of Asia-Pacific
    • 7.2.4. Middle East & Africa
      • 7.2.4.1. GCC
      • 7.2.4.2. South Africa
      • 7.2.4.3. Rest of the Middle East & Africa
    • 7.2.5. South America
      • 7.2.5.1. Brazil
      • 7.2.5.2. Argentina
      • 7.2.5.3. Rest of South America

8. Competitive Landscape

  • 8.1. Mergers and Acquisition Analysis
  • 8.2. Agreements, Collaborations, and Partnerships
  • 8.3. New Products Launches

9. Key Players

  • 9.1. Alnylam Pharmaceuticals Inc.
  • 9.2. Bavarian Nordic
  • 9.3. Cleveland BioLabs
  • 9.4. DynPort Vaccine Company LLC
  • 9.5. Elusys Therapeutics Inc.
  • 9.6. Emergent BioSolutions Inc.
  • 9.7. Ichor Medical Systems
  • 9.8. Ology Bioscience
  • 9.9. PharmAthene Inc.
  • 9.10. SIGA Technologies

List not Exhaustive

10. Future of the Market

Back to Top
전화 문의
F A Q